HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 6, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at two upcoming investor conferences: The Rodman & Renshaw 18^th Annual Global Investment Conference, and the Maxim Inaugural Israel Day.

Rodman and Renshaw 18^th Annual Global Investment Conference
Date:              Tuesday, September 13
Time:              11:15am Eastern Time
Location:        The Lotte New York Palace Hotel
Webcast:   http://wsw.com/webcast/rrshq26/bcli

Maxim Inaugural Israel Day
Date:               Wednesday, September 14
Time:              11:00am Eastern Time
Location:         405 Lexington Avenue, 2^nd Floor

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka, COO
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-two-investor-conferences-in-september-300322701.html

SOURCE BrainStorm Cell Therapeutics Inc.